Nephros, Inc.
Company & revenue
About Nephros, Inc.
Who they are
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products.
Detailed revenue, brand and relationship research has not yet been completed for NEPH.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
64
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
82
Strong
Financial Strength
87
Business Quality / Moat
87
Management
100
Growth Quality
61
Risk / Durability
55
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
77
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
73/100
Building Historical Record
Model Score 73/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as mixed to moderately strong.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Balance-sheet / debt profile scores strongly
- •Valuation scores attractively
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for NEPH
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can NEPH maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is NEPH's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is NEPH likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is NEPH's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
64
Opportunity Score
77
Market Cap
$39.8M
P/E Ratio
23.5
EPS
$0.16
52-Week High
$6.42
52-Week Low
$2.66
Beta
1.56
Intrinsic Value
$6.19
Analyst Target
$4.00
Shares Outstanding
11.0M
Total Revenue
$20.7M
Total Debt
$872K
Dividend
No current dividend
Liquidation Value / Share
$1.09
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on NEPH.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonat.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
49
Jul 24, 2026
Change
+15.0
points
Current Score
64
Oct 1, 2026
Category Changes
NEPH increased 15 points because Revenue improved by 12.9 points, Capital improved by 20 points, Management improved by 5.5 points.
Positive Contributors
- + Revenue improved by 12.9 points
- + Capital improved by 20 points
- + Management improved by 5.5 points
- + Valuation improved by 59.9 points
- + Buffett improved by 9.6 points
Projected Score
Projected Score
67
Projected Change
+3.5%
Preliminary comparable-period financial changes suggest improvement of approximately 3.5 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$3.67
Intrinsic Value
$6.19
Difference
−$2.52
-40.7% vs IV
Margin of Safety
40.7%
Related Companies
Medical - Instruments & SuppliesNews
Nephros Q2 Earnings Call Highlights
Nephros, Inc. (NEPH) Q2 2026 Earnings Call Transcript
Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026
Nephros Schedules Second Quarter 2026 Financial Results Conference Call
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial